What is TPST's market cap?

$9.26M, based on the Nov 4 close of $0.46.

Does Tempest Therapeutics pay a dividend?

No regular cash dividend has been paid in the last year.

How much of TPST is sold short?

312.9K shares, 3.1% of float, as of Oct 15, 2026.

What sector is TPST in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · TPSTHealthcarePharmaceuticals

Tempest Therapeutics, Inc. Common Stock (TPST)

$0.4633−1.13%

Close Nov 4, 2026 · split-adjusted

Nov 3, 2026$0.46▼ 90.73% in range

Nov 3, 2025Low $0.46 · High $5.01Nov 3, 2026

What changed · written from our data

As of Nov 4, 2026

Tempest Therapeutics closed at $0.46 on Nov 4, down 1.13%, within 0.0% of its 52-week closing low. Volume of 108.5K shares was 0.71× its 20-day average (below normal).

Split-adjusted performance: -41.2% over one month, -77.1% over six months, -90.8% over one year.

Short interest was 312.9K shares at the Oct 15 settlement, down 48.6% from the prior report (3.1% of float, 1.0 days to cover).

Market cap$9.3M20.0M shares

Revenue · quarter$0.00—

Diluted EPS$-0.34—

P/E · TTM—

Net margin—

Dividend yieldNone

52-week range0.46 – 5.01−90.8% from high

Volume108.5K0.71× 20-day avg

Volatility · 60d152.2%Annualised

Short % of float3.1%1.0 days to cover

Net cash$779.0KCash $779.0K

Next earnings—Not scheduled

Split-adjusted performance

1W −14.2%1M −41.2%3M −48.7%6M −77.1%YTD −67.7%1Y −90.8%3Y −98.2%5Y −99.4%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum9

Revenue growth—

Net margin—

Value (low P/E)—

Size15

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short312.9K−48.6% vs prior

Days to cover1.0Settled Oct 15

% of float3.1%

Short vol. 10d51.7%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
TPSTTempest Therapeutics	$0.4633	−1.13%	−77.1%	—	—	—	$9.3M
CALCCalciMedica	$1.35	−8.50%	−56.8%	—	—	—	$9.2M	Compare
CURXCuranex Pharmaceuticals	$5.80	−6.30%	−17.7%	—	—	—	$9.1M	Compare
ACTUActuate Therapeutics	$0.3699	+5.69%	−87.6%	—	—	—	$8.9M	Compare
MTVAMetaVia	$1.34	+6.35%	−4.3%	—	—	—	$8.8M	Compare
BFRGBullfrog AI Holdings	$0.5263	+0.59%	−25.4%	+547.6%	−636.8%	—	$9.8M	Compare
LTRNLantern Pharma	$0.5866	−2.61%	−72.6%	—	—	—	$8.8M	Compare
GTBPGT Biopharma	$4.84	−8.16%	−51.9%	—	—	—	$8.7M	Compare
TOVXTheriva Biologics	$0.1900	+4.40%	−50.3%	—	—	—	$8.7M	Compare

News about Tempest Therapeutics

All news →

Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual MeetingGlobeNewswire Inc. · Apr 29, 2026▲ Positive Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026GlobeNewswire Inc. · Mar 11, 2026▲ Positive

Quick answers

What does Tempest Therapeutics do?: Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
What is TPST's market cap?: $9.26M, based on the Nov 4 close of $0.46.
Does Tempest Therapeutics pay a dividend?: No regular cash dividend has been paid in the last year.
How much of TPST is sold short?: 312.9K shares, 3.1% of float, as of Oct 15, 2026.
What sector is TPST in?: Healthcare, in the Pharmaceuticals industry.

About Tempest Therapeutics

Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.

HQ: Brisbane, CA4 employeesListed Jun 28, 2021tempesttx.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology